Winter 2026
Program Coordinator Fellow
Pediatric Endocrinology
Updated on 9/5/2026
Wash U
Academic research and entrepreneurial institution
Compensation Overview
$23.37 - $36.19/hr
St. Louis, MO, USA
Hybrid
Hybrid work may be available after the six-month introductory period.
Bachelor's
 Administrative & Executive Assistance (1) |
|---|
- A bachelor's degree is required, although a combination of education and/or experience may substitute for the minimum education.
- A preferred bachelor's degree in a business-related field.
- Experience in a medical, research, or educational environment is preferred.
- Proficiency with computer applications is preferred.
- Knowledge of accreditation standards, database management, medical policy, spreadsheet management, and word processing is preferred.
- Ability to exercise independent judgment, communicate orally and in writing, solve problems, manage time, work independently, and demonstrate personal initiative and sound judgment is preferred.
- Manage calendars for the Fellowship Program Director and Assistant Program Director, including organizing time and travel commitments, meetings, and conference calls.
- Prepare letters, memoranda, correspondence, and contact-list updates.
- Maintain curricula vitae and biographical sketches in the Washington University Profile System.
- Assist the Fellowship Director and Assistant Director with coordinating the Pediatric Endocrinology fellowship program.
- Pre-screen fellowship candidates and coordinate fellow communications and contact lists.
- Coordinate and communicate the noon conference series schedule.
- Manage the fellowship selection process and schedule interviews for selected potential fellows.
- Serve as a liaison to internal and external agencies, including ERAS, New Innovations, GME, AMA, NRMP, ABP, ACGME, OISS, BJC-CVO, and SLCH.
- Monitor the program for compliance, create reports, and coordinate site visits.
- Enter data on the ACGME website and prepare supporting documentation for site reviews.
- Maintain and distribute the fellowship handbook annually.
- Maintain fellowship policies, procedures, objectives, regulatory records, licenses, reports, and compliance documentation.
- Provide notifications as necessary.
- Make travel arrangements, prepare visit itineraries, and assist applicants with attending appointments during visits.
- Coordinate duties required for new and graduating fellows.
- Coordinate and update fellow rotation and conference schedules, including the SLCH on-call system.
- Process visitor forms and shadow requests.
- Manage medical student clinic rotations.
- Perform other assigned duties.
Wash U translates academic research into practical technologies and programs that address global challenges. The institution supports scholars through grants and partnerships to move discoveries from the lab into the public sector via entrepreneurship and technology transfer. Unlike many traditional research institutions, Wash U emphasizes a high level of financial transparency and leverages a historical connection to Nobel Laureates to foster a collaborative environment. Its goal is to use these shared visions and research initiatives to create a more equitable future and provide tangible benefits to society.
Company Size
N/A
Company Stage
N/A
Total Funding
N/A
Headquarters
N/A
Founded
1853
Simplify's Take
What believers are saying
- WashU Innovation reported 85 FY26 patents issued and 12 new IP startups.
- WashU signed July 2026 neuroscience collaboration with Bristol Myers Squibb, funding translational training.
- Neuraptive licensed WashU's bioresorbable nerve stimulator in July 2026, validating commercialization depth.
What critics are saying
- WashU laid off 316 staff and cut 198 roles in 2025, signaling strain.
- Chancellor Martin warned of more structural budget changes after federal research funding reductions.
- A $37 million endowment-tax increase in fiscal 2026 squeezes research hiring and expansion.
What makes Wash U unique
- WashU converts lab discoveries into licenses, startups, and industry deals through OTM.
- WashU Medicine and BJC jointly run CHAI, centralizing clinically governed healthcare AI adoption.
- WashU retains top-tier NIH scale: second-largest U.S. medical school portfolio, $1B-plus annual research.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Paid Vacation
401(k) Company Match
Wellness Program
Mental Health Support
Parental Leave
Family Planning Benefits
Company News
WashU Medicine marketing and communications wins five Telly Awards. August 28, 2026 A movie trailer, local TV spot and documentaries produced by WashU Medicine Marketing & Communications recently won five Telly awards, an international contest honoring excellence in TV and video production. The 47th annual competition recognizes creators, brands and production companies from national television networks, movie studios, major brands, sports teams and universities, among others. The organization received nearly 14,000 entries, a 6% increase from last year and the most ever. And the awards go to... * "In Our Lifetime - Part 1: A Piece of Me" follows a family burdened by inherited early-onset Alzheimer's disease and the hope they find in research led by WashU Medicine. The documentary received a silver award in the category Branded Content - Documentary: Short Form (Under 40 minutes). The team included (cinematographer and editor) Huy Mach, WashU Medicine senior video producer; (producer) Macallan Lay, project manager; (director) Josh Kell, assistant vice chancellor and executive creative director; and Jessica Church, director of media relations. * "Changing What's Possible" is a powerful, 30-second look into WashU Medicine's approach to advancing medicine. The commercial received a silver award in the Local TV Craft Writing category. Recipients were Jessy Lobel, senior creative director, and Kell. * "The Cure Within" documents the first patients in the region to receive a newly approved gene therapy for sickle cell disease and the WashU Medicine physicians who made the opportunity possible. The video won two bronze medals in the categories Branded Content - Documentary: Short Form (Under 40 minutes) and Branded Content - Science & Technology. Staff members involved were Mach, Kell, Church and senior sciences writer Marta Wegorzewska. * "Another Tomorrow" features patients whose lives were transformed by a drug for a genetic form of amyotrophic lateral sclerosis (ALS). Research led by WashU Medicine served as the basis for the drug's FDA approval. The trailer received a bronze in the category Film & Shorts - Movie Trailer. Winners were Mach, Lay, Kell and Church.
A painless punch with a microneedle patch could detect kidney disease earlier. Kidney disease is silent in its early stages, progressing without symptoms until the disease is advanced. Researchers in the McKelvey School of Engineering at Washington University in St. Louis, in collaboration with researchers at WashU Medicine and at Texas A&M University, have been developing a minimally invasive method to improve diagnosis in earlier stages. New research from the lab of Srikanth Singamaneni, the Lilyan & E. Lisle Hughes Professor in the Department of Mechanical Engineering & Materials Science, shows the early success of a microneedle patch that can be applied on the skin to quickly and safely capture biomarkers and quantify them accurately. The patch detected early signs of kidney injury and may one day support home or point-of-care monitoring without requiring refrigeration. Results of their research were published online Aug. 5 in Advanced Materials. It is the first study to show that encapsulating biomolecules on microneedles preserved their biological functions. The research team, which includes Yixuan Wang, a doctoral student in Singamaneni's lab, created microneedles coated with a metal-organic framework (MOF) that can sample interstitial fluid in the skin. The microneedles are coated with a material that creates a shell that detects and preserves neutrophil gelatinase-associated lipocalin (NGAL) antibodies, which are an early biomarker of acute kidney injury. The MOF shell preserved the antibodies for up to four weeks at 50 C (122 F) without refrigeration. "This metal-organic framework encapsulation is a simple and highly effective way to create microneedle sensors that are resilient to environmental challenges and provide a scalable path to minimally invasive biosensing for at-home or remote health monitoring," Singamaneni said. NGAL increases in the blood within hours of a kidney injury and is a clinically validated biomarker for kidney damage. However, because it requires drawing blood with a needle and cold-chain logistics, it has not been useful in home-based or resource-limited settings. Previously, Singamaneni and collaborators established another type of microneedle patches that can look for biomarkers of disease. Adapting that low-cost, easy-to-use technology required them to create a biosensor with high sensitivity and a broader range, as well as addressing cold-chain logistics. Wang Y, Liu Y, Debnath A, Li C, Want Z, Kondepati G, Balmoori S, Morrissey JJ, Chen YM, Tian L, Singamaneni S. Metal-Organic Framework-Preserved Thermostable Microneedle Patch for Minimally Invasive Detection and Monitoring of Kidney Dysfunction. Advanced Materials, published online Aug. 5, 2026. DOI: https://doi.org/10.1002/adma.74423 This research was supported by funding from the National Science Foundation (CBET 2224610 and CBET 560 2316285), the National Institutes of Health (R21DK131557A1, R35 GM147568, R01 2DK105056-6 and R56DK138158A1), the Congressionally Directed Medical Research Programs (HT94252310996 and W81XWH-19-1-0320), and VA Merit (I01BX006401A1). Singamaneni and Jeremiah J. Morrissey are the inventors of the plasmonic-fluor technology, which has been licensed by the Office of Technology Management at Washington University in St. Louis.
WashU Medicine honors CEO Haruo Naito and Eisai for longstanding contributions to Alzheimer's disease research and healthcare. August 18, 2026 Eisai Co., Ltd. (Headquarters: Tokyo, "Eisai") announced today that Washington University School of Medicine in St. Louis ("WashU Medicine") held a ceremony unveiling a plaque honoring the longstanding contributions and achievements of CEO Haruo Naito and Eisai in healthcare, including in the field of Alzheimer's disease (AD). The plaque, commemorating these achievements, will be permanently displayed on a wall in the lobby of the Jeffrey T. Fort Neuroscience Research Building (NRB). CEO Haruo Naito and Eisai were recognized for their long-term and significant contributions to WashU Medicine and the Knight Family Dominantly Inherited Alzheimer Network-Trials Unit (DIAN-TU), as well as for the profound impact CEO Naito's leadership and vision have had on patients, families and researchers around the world. Eisai and WashU Medicine have been collaborating in research on neurodegenerative diseases, including dementia and Parkinson's disease. In particular, in the AD field, the Phase II/III Tau NexGen Study conducted by the Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU), led by the University's School of Medicine, is exploring the safety, tolerability, biomarkers and cognitive efficacy of Eisai's anti-MTBR (microtubule binding region) tau antibody etalanetug (E2814) for the treatment of dominantly inherited Alzheimer's disease (DIAD). In this study, the anti-amyloid beta (Aβ) protofibril antibody lecanemab was selected as the backbone anti-amyloid therapy. The collaboration between WashU Medicine neuroscience researchers and Eisai reinforces a shared mission of advancing human healthcare, which accelerates turning discoveries from medical research into solutions for patients, improving care for families today while working toward a future free of neurodegenerative disease. Media contacts: Public Relations Department, Eisai Co., Ltd.
Lee and Lee honored with prestigious Cogan Award. August 7, 2026 Aaron Y. Lee, MD, the Arthur W. Stickle Distinguished Professor of Ophthalmology and Visual Sciences and head of the John F. Hardesty, MD Department of Ophthalmology & Visual Sciences at WashU Medicine, and Cecilia Lee, MD, the Jane Hardesty Poole Distinguished Professor, have been honored with the Cogan Award in recognition of their impactful contributions to vision science and ophthalmic research. This prestigious award, presented by the Association for Research in Vision and Ophthalmology (ARVO), highlights exceptional work that propels the field forward through innovative methods and collaborative leadership. Their recognition underscores WashU Medicine's leadership in combining clinical excellence, innovative research and collaborative science to address some of the most challenging questions in vision care. Lee and Lee harness large-scale data, machine learning and advanced analytics to elucidate complex patterns in eye disease and vision loss, while also leveraging the eye as a non-invasive window into systemic health - a field known as oculomics. Their research emphasizes equitable access to data and analytic tools, ensuring that discoveries benefit diverse populations and accelerate real-world translational impact.
Which health systems have chief AI officers. Table of contents. As hospitals and health systems further embed AI into healthcare delivery, they are increasingly appointing chief AI officers or equivalent senior executives with dedicated responsibility for AI governance, implementation and oversight, reflecting a broader trend of health systems chief AI officers taking on formalized C-suite roles. Why health systems chief AI officers roles are growing. The growing presence of these roles reflects the industry's recognition that AI may pose risks to patient safety, professional liability and regulatory compliance, and thus warrants cross-functional leadership at the highest levels. Below is a look at healthcare organizations with dedicated AI leadership. Academic medical centers leading with health systems chief AI officers. Ann & Robert H. Lurie Children's Hospital of Chicago named Rajiv Kolagani as its chief data and AI officer. BJC Health System and WashU Medicine in St. Louis appointed two leaders: Philip R.O. Payne, PhD, as the inaugural chief health AI officer of WashU Medicine and BJC, and Deborah O'Dell as chief data & analytics officer at BJC. Major health systems with chief AI officers on the west coast. Cedars-Sinai in Los Angeles appointed Mouneer Odeh as its inaugural chief artificial intelligence officer at the end of 2024. City of Hope in Duarte, Calif., named Nasim Eftekhari system vice president and chief AI and analytics officer. UCLA Health named Paul J. Lukac, MD, as its chief AI officer, while UCSF Health named Sara Murray, MD, as chief health AI officer. UC San Diego Health named Karandeep Singh, MD, as its inaugural chief health artificial intelligence officer, and UCI Health in Orange, Calif., named Deepti Pandita, MD, as its chief medical informatics and AI officer. Kaiser Permanente's approach to AI leadership. Kaiser Permanente in Oakland, Calif., has Daniel Yang, MD, serving as vice president of artificial intelligence and emerging technologies, a title distinct from the "chief AI officer" designation used at many peer organizations. Midwest and southern health systems chief AI officers. Cleveland Clinic appointed Ben Shahshahani, PhD, as its first vice president and chief artificial intelligence officer in August 2024. Mayo Clinic in Rochester, Minn., appointed Micky Tripathi, PhD, as its chief AI implementation officer, while Mayo Clinic Arizona in Phoenix separately named Bhavik Patel, MD, as chief AI officer. Mercy in St. Louis named Byron Yount, PhD, as chief data and artificial intelligence officer and vice president of transformation operations. Additional regional health systems naming AI chiefs. Baptist Health System in Louisville, Ky., named Brett Oliver, MD, as its chief medical information and AI officer. Bon Secours Mercy Health in Cincinnati named Dylan Clark as its chief analytics and artificial intelligence officer. University of Utah Health in Salt Lake City appointed Kensaku Kawamoto, MD, PhD, as its first chief health AI transformation officer. UT Southwestern Medical Center in Dallas named Warren D'Souza, PhD, as its inaugural chief artificial intelligence officer, and VCU Health in Richmond, Va., named Alok Chaudhary as vice president and chief data and artificial intelligence officer. Children's Hospitals and Denver Health's AI Leadership. Children's National Hospital in Washington, D.C., named Alda Mizaku as vice president and chief data and AI officer. Denver Health named Daniel Kortsch, MD, as its associate chief of AI and digital health. Hackensack Meridian Health in Edison, N.J., named David Arnold as its senior vice president and chief AI and data officer. Variation in title and scope across these health systems chief AI officers. Across this list, titles vary meaningfully, from "chief AI officer" to "chief health AI officer" to "vice president of artificial intelligence and emerging technologies," reflecting differing organizational structures and how each health system chooses to position AI leadership relative to existing informatics, data, and analytics functions. What this wave of health systems chief AI officers means going forward. With more than 20 major health systems now represented on this list, spanning academic medical centers, children's hospitals, and regional systems across the country, the appointment of dedicated AI leadership appears to have become a standard organizational response to AI's growing role in clinical and administrative operations. Given the cross-functional nature of these roles, spanning patient safety, professional liability, and regulatory compliance, other health systems without a formally designated AI chief may increasingly feel competitive pressure to establish similar positions. What to watch going forward. As this list continues to grow, with Becker's actively soliciting additional health systems for inclusion, industry observers will likely watch which organizational models, dedicated chief AI officer roles versus AI responsibilities folded into existing chief medical information officer or chief data officer positions, prove most effective at balancing innovation with the governance and compliance demands these executives are tasked with managing. Given how recently many of these appointments occurred, with several dating to only the past one to two years, this health systems chief AI officers trend appears to still be in its early, rapidly evolving phase across the healthcare industry.